Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lineage Cell Therapeutics, Inc.
< Previous
1
2
Next >
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
November 01, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
October 24, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
September 19, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
October 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
August 29, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
October 05, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
September 13, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
August 03, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
September 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
May 22, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
September 06, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
July 24, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
May 04, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
May 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
April 26, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
March 02, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at 2023 AAPS National Biotechnology Conference
April 18, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
March 30, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
November 03, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
March 20, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
March 06, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
February 22, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
February 08, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 29, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
November 28, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.